Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: Synthesis, structure-activity relationships, and biological activities

Journal of Medicinal Chemistry

Volumn 57, Issue 6, 2014, Pages 2275-2291

  Lu, Tiangong ^b   Goh, Aik Wye ^a   Yu, Mingfeng ^a   Adams, Julian ^a   Lam, Frankie ^a   Teo, Theodosia ^a   Li, Peng ^a   Noll, Ben ^a   Zhong, Longjin ^a   Diab, Sarah ^a   Chahrour, Osama ^b   Hu, Anran ^b   Abbas, Abdullahi Y ^b   Liu, Xiangrui ^b   Huang, Shiliang ^b   Sumby, Christopher J ^c   Milne, Robert ^a   Midgley, Carol ^d   Wang, Shudong ^a,b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d OPEN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXY 3 NITRO 5 [((2,4,6 TRIMETHOXYSTYRYL) SULFONYL) METHYL] PYRIDINE; 2 METHOXY 5 [((2,4,6 TRIMETHOXYSTYRYL) SULFONYL) METHYL] PYRIDIN 3 AMINE; 2 METHOXY 5[((2,4,6 TRIMETHOXYSTYRYL) SULFONYL) METHYL] PYRIDINE 3 AMINE; 2 [(STYRYLSULFONYL) METHYL] PYRIDINE DERIVATIVE; 2[(2 METHOXY 5(((2,4,6 TRIMETHOXYSTYRYL) SULFONYL) METHYL) PYRIDIN 3 YL) AMINO] ACETIC ACID; 2[(2 METHOXY 5(((2,4,6 TRIMETHOXYSTYRYL) SULFONYL) METHYL) PYRIDIN 3 YL] AMINO ACETAMIDE; 3 [(STYRYLSULFONYL) METHYL] PYRIDINE DERIVATIVE; 6 [(STYRYLSULFONYL) METHYL] PYRIDINE 3 METHOXY 6[((2,4,6 TRIMETHOXYSTYRYL) SULFONYL) METHYL] PYRIDINE 2 AMINE DERIVATIVE; CISPLATIN; ETHYL 2[(2 METHOXY 5(((2,4,6 TRIMETHOXYSTYRYL) SULFONYL) METHYL) PYRIDIN 3 YL) AMINO] ACETATE; N ETHYL N [2 METHOXY 5 (((2,4,6 TRIMETHOXYSTYRYL) SULFONYL) METHYL) PYRIDIN 3 YL] ACETAMIDE; N ETHYL N [2 METHOXY 5(((2,4,6 TRIMETHOXYSTYRYL) SULFONYL) METHYL) PYRIDIN 3 YL] ACETAMIDE; N [2 METHOXY 5 (((2,4,6 TRIMETHOXYSTYRYL) SULFONYL) METHYL) PYRIDIN 3 YL] METHANESULFONAMIDE; N [2 METHOXY 5(((2,4,6 TRIMETHOXYSTYRYL) SULFONYL) METHYL) PYRIDIN 3 YL) ACETAMIDE; N [2 METHOXY 5(((2,4,6 TRIMETHOXYSTYRYL) SULFONYL) METHYL) PYRIDIN 3 YL] ETHANESULFORNAMIDE; N [2 METHOXY 5(((2,4,6 TRIMETHOXYSTYRYL) SULFONYL) METHYL) PYRIDIN 3 YL] PROPANE 1 SULFONAMIDE; PYRIDINE DERIVATIVE; RIGOSERTIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

AMINOPYRIDINES; ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG DISCOVERY; GLYCINE; HALF-LIFE; INDICATORS AND REAGENTS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; STYRENES; SULFONAMIDES; SULFONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897425999     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4019614     Document Type: Article

References (25)

1. Gumireddy, K.; Reddy, M. V.; Cosenza, S. C.; Boominathan, R.; Baker, S. J.; Papathi, N.; Jiang, J.; Holland, J.; Reddy, E. P. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent Cancer Cell 2005, 7, 275-286
2. Nigg, E. A. Polo-like kinases: Positive regulators of cell division from start to finish Curr. Opin. Cell Biol. 1998, 10, 776-783
3. Jackman, M.; Lindon, C.; Nigg, E. A.; Pines, J. Active cyclin B1-Cdk1 first appears on centrosomes in prophase Nat. Cell Biol. 2003, 5, 143-148
4. Wolf, G.; Elez, R.; Doermer, A.; Holtrich, U.; Ackermann, H.; Stutte, H. J.; Altmannsberger, H.-M.; Rübsamen-Waigmann, H.; Strebhardt, K. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer Oncogene 1997, 14, 543-549
5. Knecht, R.; Oberhauser, C.; Strebhardt, K. PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas Int. J. Cancer 2000, 89, 535-536
6. Weichert, W.; Denkert, C.; Schmidt, M.; Gekeler, V.; Wolf, G.; Koebel, M.; Dietel, M.; Hauptmann, S. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma Br. J. Cancer 2004, 90, 815-821
7. Weichert, W.; Kristiansen, G.; Winzer, K. J.; Schmidt, M.; Gekeler, V.; Noske, A.; Muller, B. M.; Niesporek, S.; Dietel, M.; Denkert, C. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications Virchows Arch. 2005, 446, 442-450
8. Prasad, A.; Park, I. W.; Allen, H.; Zhang, X.; Reddy, M. V.; Boominathan, R.; Reddy, E. P.; Groopman, J. E. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells Oncogene 2009, 28, 1518-1528
9. Oussenko, I. A.; Holland, J. F.; Reddy, E. P.; Ohnuma, T. Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation Cancer Res. 2011, 71, 4968-4976
10. Schoffski, P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology Oncologist 2009, 14, 559-570
11. Jimeno, A.; Li, J.; Messersmith, W. A.; Laheru, D.; Rudek, M. A.; Maniar, M.; Hidalgo, M.; Baker, S. D.; Donehower, R. C. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors J. Clin. Oncol. 2008, 26, 5504-5510
12. Olnes, M. J.; Shenoy, A.; Weinstein, B.; Pfannes, L.; Loeliger, K.; Tucker, Z.; Tian, X.; Kwak, M.; Wilhelm, F.; Yong, A. S.; Maric, I.; Maniar, M.; Scheinberg, P.; Groopman, J.; Young, N. S.; Sloand, E. M. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na Leuk. Res. 2012, 36, 982-989
13. Komrokji, R. S.; Raza, A.; Lancet, J. E.; Ren, C.; Taft, D.; Maniar, M.; Wilhelm, F.; List, A. F. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes Br. J. Hamaetol. 2013, 162, 517-524
14. Kavallieratos, K.; Bertao, C. M.; Crabtree, R. H. Hydrogen bonding in anion recognition: A family of versatile, nonpreorganized neutral and acyclic receptors J. Org. Chem. 1999, 64, 1675-1683
15. Sumby, C. J.; Hanton, L. R. Syntheses and studies of flexible amide ligands: A toolkit for studying metallo-supramolecular assemblies for anion binding Tetrahedron 2009, 65, 4681-4691
16. Chahrour, O.; Abdalla, A.; Lam, F.; Midgley, C.; Wang, S. Synthesis and biological evaluation of benzyl styrylsulfonyl derivatives as potent anticancer mitotic inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 3066-3069
17. Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.; Yuill, R.; Thomas, M.; Mezna, M.; Jackson, W.; Midgley, C.; Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S. Y.; McInnes, C.; Zheleva, D.; Walkinshaw, M. D.; Fischer, P. M. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: Synthesis, SAR analysis, X-ray crystallography, and biological activity J. Med. Chem. 2004, 47, 1662-1675
18. Jimeno, A.; Chan, A.; Cusatis, G.; Zhang, X.; Wheelhouse, J.; Solomon, A.; Chan, F.; Zhao, M.; Cosenza, S. C.; Ramana Reddy, M. V.; Rudek, M. A.; Kulesza, P.; Donehower, R. C.; Reddy, E. P.; Hidalgo, M. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay Oncogene 2009, 28, 610-618
19. Avdeef, A. pH-metric log P. II: Refinement of partition coefficients and ionization constants of multiprotic substances J. Pharm. Sci. 1993, 82, 183-190
20. Cyprotex. http://www.cyprotex.com/admepk/in-vitro-permeability/caco-2- permeability/.
21. CrysAlisPro; CrysAlis171.NET, Version 1.171.34.44; Oxford Diffraction Ltd: Oxfordshire, U.K., 2010.
22. Sheldrick, G. M. Phase annealing in SHELX-90: Direct methods for larger structures Acta Crystallogr., Sect. A: Found. Crystallogr. 1990, 46, 467-473
23. Sheldrick, G. M. SHELXL-97; University of Göttingen: Göttingen, Germany; 1997.
24. Barbour, L. J. X-Seed - A software tool for supramolecular crystallography J. Supramol. Chem. 2001, 1, 189-191
25. Wang, S.; Midgley, C. A.; Scaerou, F.; Grabarek, J. B.; Griffiths, G.; Jackson, W.; Kontopidis, G.; McClue, S. J.; McInnes, C.; Meades, C.; Mezna, M.; Plater, A.; Stuart, I.; Thomas, M. P.; Wood, G.; Clarke, R. G.; Blake, D. G.; Zheleva, D. I.; Lane, D. P.; Jackson, R. C.; Glover, D. M.; Fischer, P. M. Discovery of N -phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors J. Med. Chem. 2010, 53, 4367-4378